Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of alkaloid in preparation of medicine for bone related diseases

A technology for bone-related diseases and alkaloids, applied in the field of biomedicine, can solve problems such as limited drugs

Inactive Publication Date: 2019-12-17
黄靖
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Currently, there are limited clinical drugs for osteoporosis, fractures, and osteoarthritis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of alkaloid in preparation of medicine for bone related diseases
  • Application of alkaloid in preparation of medicine for bone related diseases
  • Application of alkaloid in preparation of medicine for bone related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Effect of alkaloids on osteoporosis

[0021] Animals: female SD rats, 3 months old, 280-320g;

[0022] Osteoporosis model: Rats were randomly divided into 3 groups, 8 in each group. After anesthesia, the rats were fixed in prone position, and the skin on both sides of the back and spine was disinfected, and then the bilateral ovaries were removed.

[0023] Grouping and administration: Rats were administered in groups on the second day after operation: the model group was administered with normal saline, 1 time / day, for 90 days; About 18-22 mg / kg), once a day, orally administered for 90 days; the tetrahydro-sartynine group was orally administered 6 mg of tetrahydro-sartynine (dose about 18-22 mg / kg), once / day, gavage for 90 days.

[0024] Index observation: On the second day after the end of the administration, the rats were anesthetized and sacrificed. The tibia of the left hind limb of each rat was removed, and the attached soft tissue was removed. The w...

Embodiment 2

[0029] Example 2 Effect of alkaloids on fracture healing

[0030] Animals: male SD rats, 300-340g;

[0031] Fracture model: after rats were anesthetized, a three-point bending method was used to create a tibial fracture in the middle and upper part of the right hindlimb tibia. Under anesthesia, a Kirschner wire was implanted into the tibia of the right hind limb, and passed through the fracture site from top to bottom in the direction of the tibial tubercle to prevent fracture dislocation. After fixation, the incision was sutured, and antibiotics were injected to prevent postoperative infection.

[0032] Grouping and administration: Fractured rats were randomly divided into 3 groups, 5 rats in each group. The model group was intragastrically administered with normal saline, once a day, for 35 days; the eugenide group was administered intragastrically with 9 mg of ketaline (dose about 26-30 mg / kg), 1 time / day, for 35 days. Days; the tetrahydrosartynine group was orally admin...

Embodiment 3

[0039] Example 3 Effect of alkaloids on arthritis

[0040] Animals: male SD rats, 160-180g;

[0041] Arthritis model: After measuring the volume of the rat's right hind paw, each rat was intradermally injected with 0.1 mL of Freund's complete adjuvant at a concentration of 10 mg / mL in the right hind paw to establish an adjuvant arthritis model.

[0042] Grouping and administration: On the day of modeling, the rats were randomly divided into 3 groups, 6 rats in each group. The model group was intragastrically administered with normal saline, once a day, for 28 days; the eugenide group was administered intragastrically with 4 mg of ketone (dose about 22-25 mg / kg), once a day, for 28 days. Day; the tetrahydrosartynine group was given 4 mg of tetrahydrosartynine (dose about 22-25 mg / kg) by gavage, once a day, for 28 days.

[0043] Index observation: On the day after the administration, the volume of the right hind paw of the rats was measured. The volume difference of the right...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine, and specifically discloses application of alkaloid in the preparation of medicine for bone related diseases. The alkaloid is selected from one of nigakinone, methylnigakinone or tetrahydroalstonine, wherein the nigakinone and the methylnigakinone show the improvement effect on osteoarthritis and osteoporosis; and the tetrahydroalstonine shows theimprovement effect on callus reconstruction in osteoporosis and traumatic fracture healing. The medicine for the bone related diseases can be one of oral medicine, external used medicine or intravenous or subcutaneous medicine.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the use of alkaloids in the preparation of medicines for bone-related diseases. Background technique [0002] Bone-related diseases include osteoporosis, fractures, osteoarthritis, etc., which are a large class of diseases that are common in real life and clinical practice. Among them, with the aggravation of aging, the absolute number of patients with osteoporosis and osteoarthritis tends to increase. With the popularization of motor vehicles and the expansion of human living space, fracture accidents caused by traffic accidents, outdoor activities, sports, etc. are also on the rise. [0003] Among them, osteoporosis is related to the abnormality of hormones such as estrogen and thyroxine abnormalities, endocrine disorders and abnormal bone metabolism caused by postmenopausal women's estrogen reduction and hyperthyroidism are common causes of osteoporosis. Some drugs, su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/437A61K31/4375A61P19/10A61P15/00A61P19/08A61P19/02A61P29/00
CPCA61K31/4375A61P19/08A61P19/10
Inventor 夏连科孙建波郭方圆郭江张伟扬子来李清洋郑春山胡明涛黄靖
Owner 黄靖
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com